Merck scores promising pivotal data on allergy treatment

Denmark's ALK-Abello is spreading the word that its Big Pharma partner, Merck, has nailed down promising data in two late-stage studies of its experimental ragweed therapy, setting the stage for a near-term marketing application for the allergy program. Abello says that the data is being held back for a future scientific conference, but adds that the ragweed treatment hit its primary endpoints.

"The data analysis shows robust results and we are looking forward to Merck's dialogue with the health authorities on the registration process for this new, innovative product," said ALK CEO Jens Bager. ALK-Abello says that about half of the 60 million Americans who suffer from allergies are hit hard by ragweed.

Merck recruited about 1,350 patients for the studies. ALK-Abello's development pact with Merck covers a range of allergy treatments developed for grass pollen allergy (Grazax), house dust mite allergy and ragweed. The biotech has two other pacts in place with Torii and Catalent.

- check out the release
- here's the story from Reuters

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.